In short
This article discusses a clinical trial investigating the long-term effects of Elivaldogene Autotemcel, also known as eli-cel or Lenti-D Drug Product, in patients with Cerebral Adrenoleukodystrophy (CALD). The study aims to monitor both the safety and effectiveness of this treatment over an extended period, providing valuable insights into its use for this rare genetic disorder.
At a glance
- Study Type
- Phase 3 long-term follow-up
- Treatment
- Elivaldogene Autotemcel (eli-cel)
- Condition
- Cerebral Adrenoleukodystrophy (CALD)
- Follow-up Duration
- Up to 15 years post-infusion
- Primary Endpoints
- MFD-free survival, malignancies, GVHD, immune-related AEs, hematologic and neurologic disorders
- Secondary Endpoints
- Subsequent stem cell transplantation, changes in NFS, absence of GdE on MRI
- Eligibility
- Previous recipients of Elivaldogene Autotemcel in parent studies
- Administration Route
- Intravenous infusion
What is Elivaldogene Autotemcel?
Elivaldogene autotemcel, also known as eli-cel or by its product name Lenti-D, is an innovative medical treatment being studied for a rare genetic disorder. It belongs to a category of treatments called advanced therapy medicinal products, specifically gene therapy. This means it uses genetic material to treat a disease.
Medical Condition Treated
Elivaldogene autotemcel is designed to treat Cerebral Adrenoleukodystrophy (CALD). CALD is a rare, genetic condition that primarily affects young boys. It's a type of adrenoleukodystrophy, which belongs to a group of disorders called congenital familial and genetic disorders. In CALD, the brain and nervous system are affected, leading to severe neurological problems if left untreated.
How Elivaldogene Autotemcel Works
Elivaldogene autotemcel is a type of cell therapy that uses the patient's own modified stem cells. Here's a simplified explanation of how it works:
- Doctors collect CD34+ hematopoietic stem cells from the patient's blood through a process called apheresis. These are special cells that can develop into various types of blood cells.
- In a laboratory, these cells are modified using a lentivirus, a type of virus that can insert genetic material into cells.
- The lentivirus adds a working copy of the ATP-binding cassette, sub-family D, member 1 (ABCD1) gene to the cells. This is the gene that's faulty in patients with CALD.
- The modified cells are then given back to the patient through an intravenous infusion (a drip into a vein).
- These modified cells can then produce the protein that CALD patients lack, potentially slowing or stopping the progression of the disease.
Clinical Trial Overview
A long-term follow-up study is being conducted to monitor the safety and effectiveness of elivaldogene autotemcel in patients with CALD who have received the treatment in previous clinical trials. This is a Phase 3 trial, which means the treatment has already shown promise in earlier studies and is now being tested in a larger group of patients.
Eligibility Criteria
To participate in this follow-up study, patients must meet the following criteria:
- Have received elivaldogene autotemcel (Lenti-D Drug Product) in a previous clinical study
- Provide written informed consent (or have it provided by a parent or legal guardian if the patient is a minor)
- Provide written informed assent, if applicable (this is when a child agrees to participate in the study)
Interestingly, there are no exclusion criteria for this study, meaning all patients who received the treatment in previous trials are eligible to participate in this long-term follow-up.
Primary Endpoints
The study will measure several key outcomes over a 15-year period after the treatment:
- Major functional disability (MFD)-free survival: This measures how long patients live without developing severe disabilities or needing a stem cell transplant.
- The number of patients who develop cancers
- The number of patients who experience graft versus host disease (GVHD), a condition where transplanted cells attack the patient's body
- The number of patients with immune-related side effects, such as autoimmune disorders or infections
- The number of patients with new or worsening blood disorders
- The number of patients with new or worsening neurological disorders
Secondary Endpoints
Additional outcomes that will be monitored include:
- The number of patients who need a second stem cell transplant
- Changes in neurological function over time
- The number of patients without signs of active brain inflammation on MRI scans
Administration and Dosage
Elivaldogene autotemcel is given as a dispersion for infusion, which means it's a liquid containing the modified cells that is infused into the patient's bloodstream. The exact dose and treatment schedule are not specified in the provided information, as they may vary based on individual patient factors.
Potential Benefits and Risks
While elivaldogene autotemcel shows promise in treating CALD, it's important to understand both the potential benefits and risks:
Potential benefits:
- Slowing or stopping the progression of CALD
- Improving survival without major functional disabilities
- Potentially avoiding the need for stem cell transplant from a donor
Potential risks:
- Development of cancers
- Graft versus host disease
- Immune-related side effects
- New or worsening blood disorders
- New or worsening neurological disorders
It's crucial to note that this treatment is still being studied, and the long-term effects are not yet fully known. This is why the 15-year follow-up study is so important. It will help researchers and doctors better understand the long-term safety and effectiveness of elivaldogene autotemcel in treating CALD.